Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTLAS: Atezolizumab + Bevacizumab + Chemo in EGFR/ALK+ NSCLC
NCT03991403Phase 3Unknown
- Sponsor
- Samsung Medical Center
- Start
- Aug 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Progression-Free Survival at 34 months. Status: unknown.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03991403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991403.